Literature DB >> 23287851

Ly6/uPAR-related protein C4.4A as a marker of solid growth pattern and poor prognosis in lung adenocarcinoma.

Benedikte Jacobsen1, Thomas Muley, Michael Meister, Hendrik Dienemann, Ib Jarle Christensen, Eric Santoni-Rugiu, Ole Didrik Lærum, Michael Ploug.   

Abstract

INTRODUCTION: We have recently shown that the protein C4.4A is induced in early precursor lesions of pulmonary adenocarcinomas and squamous cell carcinomas. In the present study, we aimed at analyzing the impact of C4.4A on the survival of non-small cell lung cancer patients and determining whether its unexpected expression in adenocarcinomas could be attributed to a specific growth type (lepidic, acinar, papillary, micropapillary, solid).
METHODS: Sections from the center and periphery of the primary tumor, as well as N2-positive lymph node metastases, were stained by immunohistochemistry for C4.4A and scored semi-quantitatively for intensity and frequency of positive tumor cells.
RESULTS: C4.4A score (intensity × frequency) in the tumor center was a highly significant prognostic factor in adenocarcinomas (n = 88), both in univariate (p = 0.004; hazard ratio [95% confidence interval] = 1.44 [1.12-1.85]) and multivariate statistical analysis (p = 0.0005; hazard ratio = 1.65 [1.24-2.19]), demonstrating decreasing survival with increasing score. In contrast, C4.4A did not provide prognostic information in squamous cell carcinomas (n = 104). Pathological stage was significant in both groups. In the adenocarcinomas, C4.4A expression was clearly associated with, but a stronger prognostic factor than, solid growth.
CONCLUSIONS: The present results substantiate the potential value of C4.4A as a prognostic marker in pulmonary adenocarcinomas seen earlier in a smaller, independent patient cohort. Importantly, we also show that C4.4A is a surrogate marker for adenocarcinoma solid growth. Recent data suggest that C4.4A is negatively regulated by the tumor suppressor liver kinase B1, which is inactivated in some adenocarcinomas, providing a possible link to the impact of C4.4A on the survival of these patients.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23287851     DOI: 10.1097/JTO.0b013e318279d503

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN: 1556-0864            Impact factor:   15.609


  15 in total

1.  The urokinase receptor homolog Haldisin is a novel differentiation marker of stratum granulosum in squamous epithelia.

Authors:  Henrik Gårdsvoll; Mette C Kriegbaum; Emil P Hertz; Warner Alpízar-Alpízar; Michael Ploug
Journal:  J Histochem Cytochem       Date:  2013-07-29       Impact factor: 2.479

2.  Comparison of the expression levels of molecular markers among the peripheral area and central area of primary tumor and metastatic lymph node tumor in patients with squamous cell carcinoma of the lung.

Authors:  Hibiki Udagawa; Genichiro Ishii; Masahiro Morise; Shigeki Umemura; Shingo Matsumoto; Kiyotaka Yoh; Seiji Niho; Hironobu Ohmatsu; Masahiro Tsuboi; Koichi Goto; Atsushi Ochiai; Yuichiro Ohe
Journal:  J Cancer Res Clin Oncol       Date:  2015-01-09       Impact factor: 4.553

3.  Expression of the Ly6/uPAR-domain proteins C4.4A and Haldisin in non-invasive and invasive skin lesions.

Authors:  Mette C Kriegbaum; Ole P F Clausen; Ole D Lærum; Michael Ploug
Journal:  J Histochem Cytochem       Date:  2014-11-20       Impact factor: 2.479

Review 4.  C4.4A as a biomarker of head and neck squamous cell carcinoma and correlated with epithelial mesenchymal transition.

Authors:  Jian-Feng Liu; Liang Mao; Lin-Lin Bu; Si-Rui Ma; Cong-Fa Huang; Wen-Feng Zhang; Zhi-Jun Sun
Journal:  Am J Cancer Res       Date:  2015-11-15       Impact factor: 6.166

Review 5.  C4.4A as a biomarker in pulmonary adenocarcinoma and squamous cell carcinoma.

Authors:  Benedikte Jacobsen; Mette Camilla Kriegbaum; Eric Santoni-Rugiu; Michael Ploug
Journal:  World J Clin Oncol       Date:  2014-10-10

6.  C4.4A gene ablation is compatible with normal epidermal development and causes modest overt phenotypes.

Authors:  Mette Camilla Kriegbaum; Benedikte Jacobsen; Annette Füchtbauer; Gert Helge Hansen; Ib Jarle Christensen; Carsten Friis Rundsten; Morten Persson; Lars Henning Engelholm; Andreas Nygaard Madsen; Ivano Di Meo; Ida Katrine Lund; Birgitte Holst; Andreas Kjaer; Ole Didrik Lærum; Ernst-Martin Füchtbauer; Michael Ploug
Journal:  Sci Rep       Date:  2016-05-12       Impact factor: 4.379

7.  High EZH2 expression is correlated to metastatic disease in pediatric soft tissue sarcomas.

Authors:  Maria Ramaglia; Velia D'Angelo; Adriana Iannotta; Daniela Di Pinto; Elvira Pota; Maria Carmen Affinita; Vittoria Donofrio; Maria Elena Errico; Angela Lombardi; Cristiana Indolfi; Fiorina Casale; Michele Caraglia
Journal:  Cancer Cell Int       Date:  2016-07-28       Impact factor: 5.722

8.  Cell-surface marker discovery for lung cancer.

Authors:  Allison S Cohen; Farah K Khalil; Eric A Welsh; Matthew B Schabath; Steven A Enkemann; Andrea Davis; Jun-Min Zhou; David C Boulware; Jongphil Kim; Eric B Haura; David L Morse
Journal:  Oncotarget       Date:  2017-12-07

9.  Expression of C4.4A in an In Vitro Human Tissue-Engineered Skin Model.

Authors:  Benedikte Jacobsen; Danielle Larouche; Olivier Rochette-Drouin; Michael Ploug; Lucie Germain
Journal:  Biomed Res Int       Date:  2017-09-07       Impact factor: 3.411

10.  Molecular signatures in IASLC/ATS/ERS classified growth patterns of lung adenocarcinoma.

Authors:  Heike Zabeck; Hendrik Dienemann; Hans Hoffmann; Joachim Pfannschmidt; Arne Warth; Philipp A Schnabel; Thomas Muley; Michael Meister; Holger Sültmann; Holger Fröhlich; Ruprecht Kuner; Felix Lasitschka
Journal:  PLoS One       Date:  2018-10-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.